BioStar merger makes Cortech instant player in in vitro diagnostics market.
This article was originally published in The Gray Sheet
Executive Summary
CORTECH SHIFTING STRATEGIC FOCUS TOWARD POINT-OF-CARE DIAGNOSTICS through acquisition of privately held BioStar, valued at about $18.7 mil. Under a definitive merger agreement announced Dec. 23, Cortech would trade 28.5 mil. new shares of common stock for all of BioStar; Cortech stock closed at 21/32 on Dec. 22. "We believe that this merger will enable us to create one of the premier point-of-care diagnostics companies in the country," BioStar President and CEO Teresa Ayers remarked.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.